Narcotic Antagonists

• 

  Subject Areas on Research

  • A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. 
  • A randomized trial of transcutaneous electric acupoint stimulation as adjunctive treatment for opioid detoxification. 
  • A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. 
  • Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. 
  • Advances in opioid antagonist treatment for opioid addiction. 
  • Anatomically dissociable effects of dopamine D1 receptor agonists on reward and relief of withdrawal in morphine-dependent rats. 
  • Antagonist treatment of opioid withdrawal translational low dose approach. 
  • Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. 
  • Antinociceptive activity of Syzygium jambos leaves extract on rats. 
  • Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness. 
  • Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal. 
  • Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. 
  • Bupropion and Naltrexone in Methamphetamine Use Disorder. 
  • Can Predictive Modeling Tools Identify Patients at High Risk of Prolonged Opioid Use After ACL Reconstruction? 
  • Central effects of morphine on GI motility in conscious dogs. 
  • Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. 
  • Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. 
  • Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. 
  • Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. 
  • Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. 
  • Criminal justice continuum for opioid users at risk of overdose. 
  • Critical opportunities for public health law: a call for action. 
  • Delta-opioid-receptor activation by [D-Pen2,D-Pen5]enkephalin and morphine inhibits substance P release from trigeminal nucleus slices. 
  • Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. 
  • Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. 
  • Does sigma receptor antagonism predict clinical antipsychotic efficacy? 
  • Dynorphin A increases substance P release from trigeminal primary afferent C-fibers. 
  • Early outcomes following low dose naltrexone enhancement of opioid detoxification. 
  • Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression. 
  • Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. 
  • Effects of atypical anxiolytic N-phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats. 
  • Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. 
  • Electroacupuncture reduces rectal distension-induced blood pressure changes in conscious dogs. 
  • Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats. 
  • Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone. 
  • Endogenous opioids regulate long-term potentiation of synaptic inhibition in the dentate gyrus of rat hippocampus. 
  • Enhanced morphine analgesia in mice lacking beta-arrestin 2. 
  • Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. 
  • Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. 
  • Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment. 
  • Facilitators and Barriers to Naloxone Kit Use Among Opioid-Dependent Patients Enrolled in Medication Assisted Therapy Clinics in North Carolina. 
  • Functional imaging of emotion reactivity in opiate-dependent borderline personality disorder. 
  • HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. 
  • Impacts of an opioid overdose prevention intervention delivered subsequent to acute care. 
  • Increasing Naloxone Prescribing in the Emergency Department Through Education and Electronic Medical Record Work-Aids. 
  • Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. 
  • Long-acting injectable naltrexone for the treatment of alcohol dependence. 
  • Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. 
  • Low-dose naloxone infusion for the treatment of intractable nausea and vomiting after intrathecal morphine in a parturient. 
  • Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective? 
  • Medication-Based Treatment to Address Opioid Use Disorder. 
  • Morphine produces a multiphasic effect on the release of substance P from rat trigeminal nucleus slices by activating different opioid receptor subtypes. 
  • Multiphasic effect of morphine on the release of substance P from rat trigeminal nucleus slices. 
  • Naltrexone blockade of nicotine effects in cigarette smokers. 
  • Naltrexone in patients with bipolar disorder and alcohol dependence. 
  • Naltrexone treatment of self-injurious behavior. 
  • Nature and Treatment of Comorbid Alcohol Problems and Post Traumatic Stress Disorder Among American Military Personnel and Veterans. 
  • Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. 
  • Opiate withdrawal in the neonatal rat: relationship to duration of treatment and naloxone dose. 
  • Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose: A Cohort Study. 
  • Opioid receptor blockade prevents propofol-induced hypotension in rats. 
  • Opioid-independent mechanisms supporting offset analgesia and temporal sharpening of nociceptive information. 
  • Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. 
  • Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. 
  • Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone. 
  • Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review. 
  • Pharmacokinetic interactions between buprenorphine and antiretroviral medications. 
  • Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. 
  • Postoperative oxycodone toxicity in a patient with chronic pain and end-stage renal disease. 
  • Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. 
  • Problem drinking and low-dose naltrexone-assisted opioid detoxification. 
  • Reduced cannabis use after low-dose naltrexone addition to opioid detoxification. 
  • Role of analgesic adjuncts in postoperative pain management. 
  • Role of mu-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. 
  • Role of noradrenergic hyperactivity in neonatal opiate abstinence. 
  • Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). 
  • Serendipitous rapid detoxification from opiates: the importance of time-dependent processes. 
  • Suppression of alcohol intake by chronic naloxone treatment in P rats: tolerance development and elevation of opiate receptor binding. 
  • T-Cell Mediation of Pregnancy Analgesia Affecting Chronic Pain in Mice. 
  • The Emergency Department as an Opportunity for Naloxone Distribution. 
  • The Opioid Epidemic in NC: Progress, Challenges, and Opportunities. 
  • The Role of Emergency Medical Services in the Opioid Epidemic. 
  • The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy. 
  • The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. 
  • The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. 
  • The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. 
  • The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats. 
  • The use of nalmefene for intrathecal opioid-associated nausea in postpartum patients. 
  • Transdermal drug delivery enhanced and controlled by erbium:YAG laser: a comparative study of lipophilic and hydrophilic drugs. 
  • Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. 
  • Treatment considerations for elderly and frail patients with neuropathic pain. 
  • Urban, individuals of color are impacted by fentanyl-contaminated heroin. 
  • Use of very low-dose naltrexone during opiate detoxification. 
  • Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. 
  • Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. 
  • [Nphe1]nociceptin(1-13)-NH2 antagonizes nociceptin-induced hypotension, bradycardia, and hindquarters vasodilation in the anesthetized rat. 
  • beta-Endorphin enhances the replication of neurotropic human immunodeficiency virus in fetal perivascular microglia. 
  • κ-Opioid receptors in the central amygdala regulate ethanol actions at presynaptic GABAergic sites. 
• 

  Keywords of People

  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine